Medtronic, a prominent medical device company, has recently initiated a recall for one of its nerve monitoring systems following reports of 10 injuries linked to the device, as announced by the Food and Drug Administration (FDA). While the devices themselves remain on the market, Medtronic has issued warnings concerning a critical malfunction where the system fails to emit a tone when in contact with a nerve, potentially resulting in severe injuries such as nerve damage.
To address this malfunction, Medtronic is in the process of deploying a software update. In the meantime, the company is advising surgeons to utilize alternative methods and rely on their surgical skills, experience, and anatomical knowledge to prevent nerve damage during operations where monitoring might be compromised.
Medtronic’s Nerve Integrity Monitor (NIM) system, which is used by healthcare professionals to locate, monitor, and stimulate nerves during surgeries, plays a critical role in preventing nerve injuries. It issues an electromyography tone when placed on a nerve to indicate its proximity and help guide the surgical procedure safely.
The recall was initiated after Medtronic received reports from customers about the system’s failure to sound an alert when positioned on a nerve, a situation termed as ‘false negatives.’ From April 2020 until the end of May 2021, Medtronic accumulated 70 reports concerning this issue. Among these were 10 serious injury reports including instances of nerve damage, facial nerve damage, nerve weakening, and nerve paralysis. One particular report highlighted the cancellation of a surgical case due to the device’s malfunction. Given the risk of severe injuries, the FDA has classified this recall as a Class I, indicating the serious nature of the health hazard involved.
The investigation into the cause of the false negatives revealed interactions between system noise and artifacts due to a fault which could affect the auto threshold and wireless muting functions if they were enabled. This resulted in the potential for false negative responses. To address and correct these issues, Medtronic has made necessary adjustments to the system, including improvements for stimulator calibration, fuse check, and data processing functions.
The new version of the NIM software, Version 1.5.4, incorporates these fixes aimed at resolving the false negative issue. Medtronic has announced plans to reach out to users for the installation of this new software version. Until this update is installed, the FDA recommends that users should adhere to medical protocols established by their organizations for monitoring patients during surgeries.
This situation underscores the importance of reliable medical device software and the impact of technological malfunctions on patient safety. The proactive measure of recalling and updating the software by Medtronic demonstrates their commitment to patient safety and the critical role of regulatory bodies like the FDA in overseeing public health concerns.
#Medtronic #recalls #nerve #monitoring #system #linked #injuries
